Brivaracetam
(2S)-2-[(4R)-2-Oxo-4-propyltetrahydro-1H-pyrrol-1-yl]butanamide
1H NMR (CDCl3, 400 MHz) 6.51 (s, 1 H) 5.93 (s, 1 H) 4.46 (dd, J = 8.9, 7.9, 1 H) 3.47 (dd, J = 9.8, 7.8 Hz, 1 H) 3.05 (dd, J = 9.8, 7.1 Hz, 1 H) 2.54 (dd, J = 16.7, 8.6, 1 H) 2.39–2.23 (m, 1 H) 2.06 (dd, J = 16.7, 8.1, 1 H) 1.99–1.85 (m, 1 H) 1.70–1.62 (m, 1 H) 1.45–1.37 (m, 2 H) 1.37–1.25 (m, 2 H) 0.94–0.84 (m, 6 H) ppm ;
13C NMR (CDCl3, 100 MHz) 175.4, 172.6, 55.7, 49.4, 37.8, 36.4, 31.9, 21.2, 20.5, 13.9, 10.4 ppm;
HRMS calculated for [M+H] C11H21O2N2 213.1603, found 213.1607.
Brivaracetam 1, (2S)-2-[(4R)-2-oxo-4-propyltetrahydro-1H-pyrrol-1-yl]butanamide, also referred to as ucb 34714, is a novel antiepileptic drug (AED) with a high-affinity for synaptic vesicle protein 2A ligand (SV2A) that successfully went through clinical phase III. Brivaracetam 1 was recently approved in Europe and United States as adjunctive therapy in the treatment of partial onset seizures in patients of 16 years age and older with epilepsy under the trade name of Briviact.
http://pubs.acs.org/doi/full/10.1021/acs.oprd.6b00094
////////////
At Hydra (Ydra) Island Greece.
.
////////////
